0.29 USD
+0 (+0.35%)
0.3049 USD
+0.01 (+5.14%)
ChartMill assigns a Buy % Consensus number of 82% to AKTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.62. This target is 1494.47% above the current price.
AKTX was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AKTX.
In the previous month the buy percentage consensus was at a similar level.
AKTX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-18 | Maxim Group | Initiate | Buy |
| 2022-12-05 | HC Wainwright & Co. | Initiate | Buy |
| 2022-11-01 | Alliance Global Partners | Initiate | Buy |
AKARI THERAPEUTICS PLC-ADR / AKTX FAQ
What is the average price target for AKARI THERAPEUTICS PLC-ADR (AKTX) stock?
9 analysts have analysed AKTX and the average price target is 4.62 USD. This implies a price increase of 1494.47% is expected in the next year compared to the current price of 0.29.
How do analysts rate AKARI THERAPEUTICS PLC-ADR (AKTX)?
The consensus rating for AKARI THERAPEUTICS PLC-ADR (AKTX) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.